July 11 (Reuters) - Biocon Ltd:
* SAYS DRUG ITOLIZUMAB RECEIVES DRUGS CONTROLLER GENERAL OF INDIA’S APPROVAL FOR ITS USE IN MODERATE TO SEVERE COVID-19 PATIENTS
* BIOCON SAYS ITOLIZUMAB WILL BE MANUFACTURED AND FORMULATED AS AN INTRAVENOUS INJECTION AT CO’S BIO-MANUFACTURING FACILITY IN BENGALURU, INDIA Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.